[Seoul Economy TV=Reporter Kim Hye-young] GWB Tech announced on the 19th that it would invest in its subsidiary S&P Genetics and NParticle, a company specializing in microfluidic technology-based particle manufacturing. In addition, a joint business agreement was signed for gene therapy and vaccine consignment production.
With this agreement, we will use NParticle’s microfluidic technology-based production equipment (hereinafter referred to as ‘MF equipment’) to conduct a gene therapy and vaccine consignment production business based on GWB Tech’s lipid nanoparticle (LNP) production technology. Formation of strategic partnerships and joint projects for EnParticle is a company that possesses particle mass production platform technology using microfluidics, and specializes in micro/nano size high value-added particles and capsule materials.
NParticle’s MF equipment will be installed and supplied to the GMP standard production facility that GWB Tech will build in the future. In addition, joint research, including related product development, will be conducted. In addition, GWB Tech is an official distributor and plans to supply NParticle’s proprietary microfluidic lab equipment to Korea.
A company official said, “We recently secured a patented technology related to LNP core materials through a bio venture company Enhanced Bio. seadaily.com